42.80
0.12%
-0.05
After Hours:
42.17
-0.63
-1.47%
Soleno Therapeutics Inc stock is currently priced at $42.80, with a 24-hour trading volume of 577.73K.
It has seen a -0.12% decreased in the last 24 hours and a -15.25% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $43.23 pivot point. If it approaches the $42.29 support level, significant changes may occur.
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Soleno Therapeutics Inc (SLNO) Net Income 2023
SLNO net income (TTM) was -$38.99 million for the quarter ending December 31, 2023, a -62.00% decrease year-over-year.
Soleno Therapeutics Inc (SLNO) Cash Flow 2023
SLNO recorded a free cash flow (TTM) of -$24.94 million for the quarter ending December 31, 2023, a -19.94% decrease year-over-year.
Soleno Therapeutics Inc (SLNO) Earnings per Share 2023
SLNO earnings per share (TTM) was -$2.9966 for the quarter ending December 31, 2023, a +0.77% growth year-over-year.
Soleno Therapeutics Inc Stock (SLNO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Hirano Patricia C | SEE REMARKS |
Jan 25 '24 |
Sale |
48.30 |
832 |
40,186 |
43,142 |
Yen Kristen | SEE REMARKS |
Jan 25 '24 |
Sale |
48.30 |
397 |
19,175 |
25,640 |
Hirano Patricia C | See Remarks |
Dec 14 '23 |
Sale |
36.49 |
1,359 |
49,584 |
19,974 |
Yen Kristen | See Remarks |
Dec 13 '23 |
Option Exercise |
2.55 |
17,916 |
45,644 |
19,953 |
Yen Kristen | See Remarks |
Dec 13 '23 |
Sale |
37.76 |
17,916 |
676,557 |
2,037 |
Hirano Patricia C | See Remarks |
Dec 13 '23 |
Sale |
38.79 |
4,885 |
189,513 |
21,333 |
Yen Kristen | See Remarks |
Dec 12 '23 |
Sale |
36.95 |
19,913 |
735,874 |
2,037 |
Mackaness James H | Chief Financial Officer |
Dec 11 '23 |
Option Exercise |
2.60 |
15,000 |
38,925 |
44,610 |
Anish Bhatnagar | Chief Executive Officer |
Dec 11 '23 |
Sale |
35.67 |
93,408 |
3,331,701 |
24,297 |
Mackaness James H | Chief Financial Officer |
Dec 11 '23 |
Sale |
36.41 |
32,482 |
1,182,828 |
12,128 |
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
GlobeNewswire Inc.
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going
Zacks Investment Research
Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength
Zacks Investment Research
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Cap:
|
Volume (24h):